Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026)

Neumora Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 5.73% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $24.8 million (down 5.73% YoY), while the FY2025 annual figure was $28.8 million, up 188.6% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $24.8 million, down from $28.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $28.8 million in Q4 2025, with the low at $4.7 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $10.0 million (2023), against an average of $15.3 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 62.12% in 2024, then soared 463.78% in 2025.
• Neumora Therapeutics' Accumulated Expenses stood at $8.4 million in 2022, then advanced by 19.18% to $10.0 million in 2023, then dropped by 0.36% to $10.0 million in 2024, then surged by 188.6% to $28.8 million in 2025, then decreased by 13.97% to $24.8 million in 2026.
• Business Quant data shows NMRA's Accumulated Expenses at $24.8 million in Q1 2026, $28.8 million in Q4 2025, and $25.0 million in Q3 2025.